<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882788</url>
  </required_header>
  <id_info>
    <org_study_id>NDO</org_study_id>
    <nct_id>NCT03882788</nct_id>
  </id_info>
  <brief_title>The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)</brief_title>
  <acronym>NDO</acronym>
  <official_title>Anesthesia and the Developing Brain: a Comparison of Two Anesthetic Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Gerber Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the type of anesthesia, narcotic-based versus&#xD;
      inhalational anesthesia administered during cardiopulmonary bypass (CPB) surgery contributes&#xD;
      to the wide variation in neurologic recovery and developmental outcome after surgery in&#xD;
      infants with congenital heart disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be consented prior to participation in this study and prior to&#xD;
      randomization.&#xD;
&#xD;
      All the subjects enrolled in the study will receive a preoperative assessment by one of the&#xD;
      cardiac anesthesiologists and receive standardized induction with sevoflurane up to 2%, 2&#xD;
      mcg/kg of fentanyl and 1 mg/kg of rocuronium. The anesthetic maintenance will be determined&#xD;
      using a computer- generated randomization table and assigning each patient to one of the two&#xD;
      anesthetic regimens. Both of these anesthetic techniques are standard of care and are&#xD;
      commonly used for these procedures.&#xD;
&#xD;
      Anesthetic Technique:&#xD;
&#xD;
      Volatile anesthetic:&#xD;
&#xD;
      In volatile anesthetic technique, maintenance of anesthesia will be standardized to the&#xD;
      volatile anesthetic isoflurane. Isoflurane will be used for the study since this is what is&#xD;
      presently available on the CPB machines. Anesthesia at 1.0 minimum anesthetic concentration&#xD;
      (MAC) indicates that at this concentration 50% of the patients will not move when surgically&#xD;
      stimulated. Anesthesiologists commonly use about 1.2-1.4 MAC in neonates, since the MAC value&#xD;
      in infants is higher than that of children and adults. Isoflurane will be delivered at&#xD;
      1.5-2.0%% as required for anesthetic management.&#xD;
&#xD;
      Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be&#xD;
      administered at no greater than 2 mcg/kg/hr.&#xD;
&#xD;
      Narcotic-based anesthetic:&#xD;
&#xD;
      In narcotic based anesthetic technique, no volatile anesthetics will be used except during&#xD;
      induction.&#xD;
&#xD;
      Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.&#xD;
&#xD;
      The anesthetic may be supplemented with dexmedetomidine 0.05 mcg/kg/hr but not to exceed 1.0&#xD;
      mcg/kg/hr. Narcotic-based anesthetic will be used by the cardiac anesthesia team and the CPB&#xD;
      technician throughout the operative case. 5 mcg/kg/hr of fentanyl is felt to represent 0.6&#xD;
      MAC of anesthesia.&#xD;
&#xD;
      Postoperative Sedative and Analgesic Care:&#xD;
&#xD;
      As per institutional standard of care, postoperative sedation will consist of fentanyl&#xD;
      infusions of 2-4 mcg/kg/hr for the first 48 hours postoperatively.&#xD;
&#xD;
      A total of 9 Blood samples will be collected at different time points throughout the entire&#xD;
      study for metabolomics determination (NAA/Cr and Chol/Cr)&#xD;
&#xD;
      EEG monitoring will be done for baseline in the pre-operative period for 15-20 minutes,&#xD;
      during surgery and post-operatively up to 48 hours and prior to discharge for 15-20 minutes.&#xD;
      Neurological and behavioral testing including Bayley Exam III will be done at 12-48 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2013</start_date>
  <completion_date type="Actual">November 19, 2020</completion_date>
  <primary_completion_date type="Actual">November 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>EEG, metabolic/NMRS analysis and neurodevelopment outcome is blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Bayley III</measure>
    <time_frame>18 months</time_frame>
    <description>Neurodevelopmental assessment scores are age dependent and based motor and behavioral abilities, often reported for normal or abnormal for age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electroencephalogram</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Brain electrical activity: observation is for brain region specific abnormal or seizure activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Choline</measure>
    <time_frame>0-72 hours</time_frame>
    <description>blood levels: time and patient dependent variation, observed patient related trends over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutamate</measure>
    <time_frame>0-72 hours</time_frame>
    <description>blood levels:time and patient dependent variation, observed patient related trends over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>n-acetylaspartate (naa)</measure>
    <time_frame>0-72 hours</time_frame>
    <description>blood levels:time and patient dependent variation, observed patient related trends over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate</measure>
    <time_frame>0-72 hours</time_frame>
    <description>blood levels:time and patient dependent variation, observed patient related trends over time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Anesthesia; Adverse Effect</condition>
  <condition>Congenital Heart Disease</condition>
  <condition>Neurodevelopmental Disorders</condition>
  <arm_group>
    <arm_group_label>Volatile Anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane.&#xD;
Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narcotic based anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In narcotic based anesthetic technique, no volatile anesthetics will be used past induction.&#xD;
Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoflurane</intervention_name>
    <description>Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management.</description>
    <arm_group_label>Volatile Anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.</description>
    <arm_group_label>Narcotic based anesthesia</arm_group_label>
    <arm_group_label>Volatile Anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neonates of at least 32 weeks of gestation, infants and children up to 2 years of age&#xD;
             admitted to The Children's Hospital for treatment of cyanotic or non-cyanotic heart&#xD;
             disease requiring surgical intervention.&#xD;
&#xD;
          -  Admitting diagnosis of cyanotic or non-cyanotic heart disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neonates less than 32 weeks of gestational age, and children more than 2 years of age.&#xD;
&#xD;
          -  Any documented central nervous system malformations.&#xD;
&#xD;
          -  Any potential subject requiring unexpected postoperative Extracorporeal membrane&#xD;
             oxygenation (ECMO) support&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa W Faberowski, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Childrens hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 5, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Lisa Wise-Faberowski</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Neurodevelopmental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

